Next Article in Journal
Formulation of Chewable Tablets Containing Carbamazepine-β-cyclodextrin Inclusion Complex and F-Melt Disintegration Excipient. The Mathematical Modeling of the Release Kinetics of Carbamazepine
Previous Article in Journal
Mesenchymal Stem Cells Engineered by Nonviral Vectors: A Powerful Tool in Cancer Gene Therapy
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling

by
Stanislav Ermolaev
1,*,
Aino Skasyrskaya
1 and
Aleksandr Vasiliev
1,2
1
Institute for Nuclear Research of Russian Academy of Sciences, 60-Letiya Oktyabrya Prospekt 7a, 117312 Moscow-Troitsk, Russia
2
Department of Chemistry, Lomonosov Moscow State University, GSP-1, Leninskie Gory, 119991 Moscow, Russia
*
Author to whom correspondence should be addressed.
Pharmaceutics 2021, 13(6), 914; https://doi.org/10.3390/pharmaceutics13060914
Submission received: 1 May 2021 / Revised: 12 June 2021 / Accepted: 17 June 2021 / Published: 21 June 2021
(This article belongs to the Section Pharmaceutical Technology, Manufacturing and Devices)

Abstract

:
A new two-column 225Ac/213Bi generator was developed specifically for using 225Ac containing an impurity of long lived 227Ac. The parent 225Ac was retained on the first Actinide Resin column, while 213Bi was accumulated on the second column filled with AG MP-50 resin via continuous elution and decay of intermediate 221Fr. The 213Bi accumulation was realized in circulation mode which allowed a compact generator design. It was demonstrated that 213Bi could be quickly and effectively extracted from AG MP-50 in form of complexes with various chelating agents including DTPA and DOTA. The performance of the generator presented and a conventional single-column generator on the base of AG MP-50 was tested and both generators were loaded with 225Ac containing 227Ac impurity. The 213Bi generation efficiencies were comparable and greater than 70%, whereas the developed generator provided a deeper degree of purification of 213Bi from Ac isotopes and decay products of 227Ac.

1. Introduction

The radionuclide, 213Bi, is considered as one of the promising radionuclides for targeted therapy of cancer [1,2]. Radiopharmaceuticals containing 213Bi are successfully passing clinical trials for the treatment of leukemia [3], NHL [4], carcinoma [5], neuroendocrine tumor [6], glioma [7], and melanoma [8]. In many cases, radiopharmaceuticals 213Bi-DOTATOC and 213Bi-PSMA-617 have shown high efficacy even after treatment with conventional therapies has failed [6,9].
The radionuclide, 213Bi, is a decay product of another promising alpha emitter 225Ac, which is used by itself [10,11] or as a parent radionuclide for 225Ac/213Bi generators. A single-column “direct” generator developed at the Institute of Transuranic Elements (ITU) and based on a strongly acidic cation-exchange sorbent AG MP-50 [12] is most commonly used. Other generators based on extraction chromatographic [13,14], ion exchange [15], and inorganic sorbents [16,17] are also available.
The radionuclide, 213Bi, has a relatively short half-life (46 min) and, therefore, it is preferable to use low molecular weight peptides and antibodies with fast pharmacokinetics as vectors for its delivery. For the same reason, significantly high activities of 213Bi are required to achieve a therapeutic effect. Depending on the vector molecules, a possible range of 213Bi administered dose may vary within 5–10 GBq [1].
Carrier-free 225Ac is applied as a source of 213Bi for conducting clinical trials of 213Bi-containing radiopharmaceuticals. It is obtained by the generator method from 229Th (T1/2 = 7.340 y) and the stock supplies are extremely limited. The world production of 225Ac by this method is no more than 70 GBq per year [2]. The main alternative method of 225Ac production is the irradiation of natural thorium with medium-energy protons. This method is being actively developed at INR RAS (Moscow-Troitsk, Russia) [18,19,20,21], TRIUMPH (Canada) [22], and LANL-BNL-ORNL (tri-lab, USA) [23]. The routine production of actinium will be launched at the accelerators of these scientific centers in the coming years, which makes it possible to produce several curies of 225Ac in one irradiation session (7–10 days). 225Ac from irradiated thorium contains a chemically inseparable impurity of long-lived 227Ac (~0.2% at the end of bombardment, EOB) [19]. Furthermore, although it was shown that such actinium can be used for therapy along with those that are generator-produced without any side effects [24], this imposes additional requirements on the 225Ac/213Bi generator. The generator system should not only provide a high yield of 213Bi in its rapid production and possess high radiation resistance [25] but also ensure a high degree of purification from both actinium isotopes and 227Ac decay products (227Th and 223Ra).
The article presents and investigates an original model of 225Ac/213Bi generator intended for utilizing the parent 225Ac with 227Ac impurity. The generator provides a fast production of 213Bi deeply purified from actinium isotopes 227Th and 223Ra. It consists of two chromatographic columns; 225Ac is firmly fixed on the first column and, as a result of mobile phase circulation, 213Bi is separated from 225Ac via continuous elution and decay of intermediate 221Fr and is concentrated on the second column. 213Bi can be efficiently and quickly stripped off by complexing agents (DTPA, DOTA, etc.), which greatly simplifies the labeling procedure.

2. Materials and Methods

All chemicals were of p.a. (pro analysis) quality or higher, obtained from Merck (Darmstadt, Germany), and used without additional purifications. All experiments were carried out using de-ionized “Milli-Q” water (18 MΩ·cm−1). Actinide Resin (P,P′-di(2-ethylhexyl)methanediphosphonic acid as an extracting agent on a silica support) with 100–150 μm particle size was obtained from Triskem, France. Biotechnology grade AG MP-50 (strong-acid cation exchange resin composed of sulfonic acid functional groups attached to a styrene divinylbenzene copolymer lattice) with 106–250 μm particle size was obtained from BioRad, Hercules, CA, USA.
γ-Ray spectroscopy with high-purity Ge-detector (HPGe) GR3818 (Canberra Industries, Inc., Meriden, CT, USA) was used for radionuclide determination. γ-Ray spectra were analyzed using software Genie 2000 (Canberra Industries, Inc., Meriden, CT, USA) and BNL-database [26].
The experiments were carried out at the temperature of 21 ± 2 °С.

2.1. Radionuclides

225Ac and 223Ra were produced at the linear proton accelerator of the Institute for Nuclear Research of the Russian Academy of Sciences (INR RAS, Troitsk-Moscow, Russia) by irradiation of thorium plates (1–2 mm thick) with protons of initial energy 120 MeV and isolated by liquid–liquid extraction, ion-exchange, and extraction chromatography in accordance with the reported procedures [20,27]. Impurity of 227Ac in actinium was determined as ~0.2% of 225Ac activity calculated at EOB. The yield and purity of the obtained radionuclides were controlled by γ-ray spectroscopy. The γ-lines 218.1 keV (abundance 11.4%), 440.5 keV (abundance 25.9%), 236.0 keV (abundance 12.9%), and 154.2 keV (abundance 5.7%) were chosen for 221Fr (T1/2 = 4.9 min), 225Ac (T1/2 = 9.9 d, through 221Fr), 213Bi (T1/2 = 46 min), 227Th (T1/2 = 18.7 d), and 223Ra (T1/2 = 11.43 min) quantification, respectively.
The stock solution of 207Bi (T1/2 = 31.55 y) in 1 M HCl (0.1 MBq/mL) was purchased from JSC Cyclotron (Russia). The γ-line 569.7 keV (abundance 97.7%) was used for 207Bi determination.

2.2. Batch Adsorption of Ra(II) and Bi(III) onto AG MP-50 Resin

Since AG MP-50 could contain impurities of calcium [28], it was previously purified. The resin was packed into large columns (1 cm inner diameter) and the calcium was eluted with 5 M HNO3, until the eluate was free from calcium, rinsed with distilled water, and dried at 60 °C to constant weight.
The adsorption of 207Bi and 223Ra from nitric and hydrochloric acid solutions onto AG MP-50 was investigated by mixing 5 mL of the acid solution with 0.1 mL of 207Bi or 223Ra containing spike and 0.05 g of the sorbent in plastic tubes. The samples were prepared with various acid concentrations (0.05–1 M), taking into account the content of nitric or hydrochloric acid in the spike solution. Tubes were shaken at room temperature for 40 min. According to the preliminary kinetic studies, this time period was enough to reach the sorption equilibrium. The amount of 1.5 mL aliquots of the aqueous solutions was taken for γ-ray spectroscopy after equilibration. Mass distribution ratios (Dm), mL/g, were calculated using the well-known equation [29].
Measured activities of 223Ra were corrected for decay. Uncertainties of activity measurements did not exceed 10%.

2.3. Column Measurement of Capacity Factors of Fr(I) onto Actinide Resin

221Fr was separated from 225Ac adsorbed onto the Actinide Resin column (0.3 or 0.4 mL) by passing neutral (pH ~6) solutions of NaCl or NH4Cl in a concentration range of 0.0017–0.1 M. The flow rate controlled by a peristaltic pump varied from 0.2 to 1 mL/min. The eluate was collected by portions during 10–20 min. In each portion, the 221Fr activity was measured immediately and decay-corrected to the end of portion sampling. Capacity factors (k’) were estimated according to the procedure reported [30].

2.4. Column Measurement of Capacity Factors of Fr(I) and Bi(III) onto AG MP-50 Resin

Four columns were filled with AG MP-50 resin of volume 0.1 mL each. The columns were connected in series and attached to the exit of 225Ac-loaded Actinide Resin column. Solution of 0.25 M HNO3 or 0.017 M NaCl was passed through the column assembly for no less than 4 h. The flow rate controlled by a peristaltic pump varied from 0.3 to 2.8 mL/min. Having finished the elution, the columns were dismounted and the 221Fr and 213Bi activities in each column were measured and decay-corrected to the end of elution. Capacity factors (k’) were estimated according to the procedure reported [30].

2.5. Preparation and Milking 225Ac/213Bi Generator “Afrabis”

The amount of 0.1 MBq of 225Ac (with the 227Ac impurity) was dissolved in 5 mL of 0.1 M HNO3 and loaded with the help of a peristaltic pump slowly on the pre-packed and conditioned column containing 0.4 mL of Actinide Resin. The second column was filled with 0.4 mL of AG MP-50 resin and both columns were connected to form a closed-loop circuit as shown in Figure 1. The Actinide Resin column was scanned on a γ-ray spectrometer through a 1.5 mm wide slit between the lead blocks immediately after preparation and after milking.
One cycle of a possible procedure for 213Bi generation was as follows:
  • The first column was washed from the accumulated 223Ra with 15–20 mL of 0.25 M HNO3;
  • Then, continuous separation of the intermediate daughter radionuclide 221Fr from 225Ac for ~4 h was occurring circularly (Figure 1) at flow rate 1–1.5 mL/min;
  • 213Bi was desorbed from the AG MP-50 column with six 0.5 mL portions of a 0.1 M HCl/0.1 M KI solution at flow rate 1 mL/min.
The desorption of 213Bi from an AG MP-50 column with DTPA solutions of various concentrations and pH values was studied. An acetate buffer solution was prepared: 3.33 g of sodium hydroxide was mixed with 5.7 mL of glacial acetic acid and the total volume was adjusted to 100 mL with distilled water (pH 5.3). DTPA was dissolved in the resulting solution to the desired concentration (10−2–10−5 M). A solution with the desired pH value (2–5.3) was obtained by adding solutions of sodium hydroxide and nitric acid. The amount of 5 mL of 0.25 M HNO3 containing 207Bi spike was slowly loaded with the help of a peristaltic pump on the pre-packed and conditioned column containing 0.4 mL of AG MP-50. Bi was eluted from the column with 5 mL of DTPA solution in an acetate buffer with DTPA concentration and pH value in the investigated range. After that, the column was washed with 5 mL 6 M HCl for desorption of residue Bi and pre-conditioned with 0.25 M HNO3 for the next Bi sorption.
In order to test desorption of 207Bi with a DOTA solution, the AG MP-50 resin with 207Bi adsorbed on it was removed from the column, mixed with 3 mL of 10−5 M DOTA, and placed in a thermostat at 90 °C with stirring for 5 or 10 min. The solution was decanted through a quartz wool filter and measured by γ-ray spectroscopy.

2.6. Preparation and Milking A Single-Column 225Ac/213Bi Generator with AG MP-50

The amount of 0.1 MBq of 225Ac (with the 227Ac impurity) was dissolved in 2.8 mL of 4 M HNO3 and loaded slowly with the help of a peristaltic pump on a pre-packed and conditioned column filled with 0.33 mL of AG MP-50 resin. Afterwards, the column was washed with 1 mL 0.05 M HNO3, 2 mL 2 M HCl, and finally with 0.01 M HCl [12,31]. As a result, 225Ac was distributed within the first half of the column. The column was scanned on a γ-ray spectroscopy through a 1.5 mm wide slit between the lead blocks.
The 213Bi was eluted with a mixture of 0.1 M NaJ/HCl solution followed by washing with 0.01 M HCl. The resulting 213Bi solution with a total volume of 3 mL was measured on a γ-ray spectrometer immediately after milking and again 6 h later. The latter measurement was conducted after the complete decay of 213Bi to determine the impurity of long-lived radionuclides—225Ac, 227Th, and 223Ra.The generator was stored wet in the 0.01 M HCl until the next use. Seven elutions of 213Bi were carried out during 1 month of the generator exploitation.

3. Results and Discussion

The ever-growing application of radionuclide generators in nuclear medicine [32] stems from the fact that a short-lived daughter radionuclide can be repeatedly reproduced and used for a long period of time; this is mainly dependent on the half-life of the parent radionuclide. Operation of most generators comprises two basic stages: accumulation and separation. First a daughter radionuclide accumulates up to transient equilibrium with the parent. Usually, both radionuclides reside together in a generator at this stage. Then the daughter is separated and recovered from the generator as fast as possible to reduce decay losses and the next generation cycle begins.
Operation mode of the generator presented here and named “Afrabis” (acronym: A—actinium-225, fra—francium-221, and bis—bismuth-213) is different. Formation and concentration of 213Bi take place in the course of permanent separation of intermediate 221Fr from 225Ac fixed on a mother column (Figure 1) and its decay.
As a result of dynamic accumulation arranged in circulation mode, 213Bi proves to already be removed from the mother column and concentrated on the second column to the moment when it reaches the transient equilibrium with 225Ac (it takes ~5–6 half-lives of 213Bi). Finally, 213Bi is extracted in a small volume of appropriate solution. Overall, 213Bi yield consists of the efficiency of single steps, namely, 221Fr elution, 213Bi concentration, and subsequent extraction from the generator.

3.1. Elution of 221Fr from the Column Containing 225Ac

Strong retention of 225Ac is necessary for long-term elution of 221Fr; this is why the extraction chromatographic sorbent Actinide Resin demonstrating high affinity to Ac(III) in mineral acid media [33,34] was chosen for a mother column. The behavior of 221Fr on Actinide Resin was studied via relatively fast elution by portions and the activity of 221Fr in each portion is corrected towards the end of portion sampling. The typical shape of 221Fr elution curve is shown in Figure 2.
The first part of the curve represents, mainly, the elution of 221Fr, which was in transient equilibrium with 225Ac at the start of elution. This part of 221Fr was stripped off in a small bolus-like volume of eluate. The volume Vmax corresponding to maximum of bolus peak (Figure 2) was used for evaluation of capacity factor k’ of Fr(I):
k   = V max V c V c = 1 q 2 Q q 2 Q
where Vc denotes the free volume of sorbent packing accessible for mobile phase (eluent), Q denotes flow rate of eluent, and q2 denotes the rate of 221Fr movement through the sorbent.
Then, the elution curve reached a plateau caused by the amount of 221Fr produced during the elution and immediately washed out. It is the 221Fr that is responsible for 213Bi production in the generator “Afrabis”. The activity of 221Fr in a portion of plateau-part of the elution curve depends on the residence time Vc/q2 of 221Fr in the chromatographic column [30]. The values of q2 obtained from the plateau-part of curve also served for k’ Fr(I) evaluation. Normally, the k’ values determined from both bolus and plateau parts of elution curve were close.
221Fr was easily separated from 225Ac adsorbed onto Actinide Resin with diluted solutions of mineral acids [30]. Elution of 221Fr from a mother column filled with inorganic sorbent on the base of TiO2·xH2O was carried out with neutral NH4Cl solutions [35]. In this work, we report data on capacity factor k’ of Fr(I) onto Actinide Resin in neutral (pH ~6) NaCl and NH4Cl solutions (Figure 3).
The efficiency of 221Fr elution with HNO3 and salt solutions was found to be comparable. This means that we are able to use neutral diluted NaCl solution, e.g., physiological saline, in the generator “Afrabis” at the stage of 213Bi accumulation, which reduces radiolytic impact on the resin.
Depending on the time of residence in column, some part of 221Fr decays into 213Bi, for which its retention on Actinide Resin is rather strong. For example, the k’ value of Bi(III) in 0.25 M HNO3 was estimated at 4·103 [30]. Therefore, it seems reasonable to use the flow rate of mobile phase as high as possible in order to diminish 213Bi losses on the mother column during the accumulation stage, as it is shown in Figure 4.
However, the increase of flow rate results in the growth of solution volume passed through the mother column because the duration of the accumulation stage cannot be significantly shortened and is determined by the time required for attaining the transient equilibrium of 213Bi to 225Ac (~5–6 half-lives of 213Bi). The large solution volume may, in turn, promote the breakthrough of 225Ac and 227Ac/227Th adsorbed on Actinide Resin (data on the distribution of long-lived radionuclides along the Actinide Resin column is reported below). Thus, the choice of optimal flow rate for the accumulation stage is a compromise of two opposite factors.

3.2. Concentrating 213Bi Apart from 225Ac

The next point after separation of 221Fr from the mother column consists in selecting the conditions for concentrated 213Bi accumulation. 221Fr may be allowed to move long enough in a certain reservoir, for example, in form of tube in order to decay into 213Bi before the latter is captured [30]. Another approach is related to the retarding 221Fr in the appropriate chromatographic medium specific to ions of heavy alkali metals. A number of sorbents including AMP-PAN (Triskem Int.), Dowex 50 × 8 [30], and inorganic sorbent modified with nickel-potassium hexacyanoferrate(II) (sorbent T-35 manufactured by “Termoxid” company, Russia) [35] were tested. The present work focuses on the investigation of macroreticular cation exchange resin AG MP-50, which is also promising for 213Bi retention and consecutive extraction from the generator.
Adsorption of 221Fr and 213Bi onto AG MP-50 was studied according to the procedure described earlier in detail [30]. The mother 225Ac column was connected to four successive columns with AG MP-50 of a small volume (0.1 mL). The solution of 0.25 M HNO3 or 0.017 M NaCl was passed through the chromatographic system for no less than 4 h to attain transient equilibrium in the 225Ac  221Fr  213Bi chain. Then the system was dismounted and γ-ray spectroscopic measurements of each column were performed. 213Bi distribution between four AG MP-50 columns as a function of flow rate of 0.25 M HNO3 solution is shown in Figure 5. Similarly, the 213Bi distribution for 0.017 M NaCl solution was obtained.
Following the procedure [30], the experimental data were used for estimation of capacity factors k’ of Fr(I) onto AG MP-50 resin from 0.25 M HNO3 and 0.017 M NaCl solutions. Predictably, adsorption of 213Bi onto AG MP-50 was high and so it was only possible to set an upper limit for k’ of Bi(III). The results are presented in Table 1 in comparison with the data reported earlier.
According to the results obtained, AG MP-50 can serve as a sorbent of second column for 213Bi accumulation. A small amount of AG MP-50 within 0.3–0.4 mL is sufficient for significant retention of 213Bi and this means that 213Bi can be further recovered from the generator in a more concentrated form.
Comparison of 221Fr sorption on two cation exchange resins Dowex 50 × 8 and AG MP-50 from 0.25 M HNO3 solution reveals (Table 1) that the k’ values of Fr(I) onto AG MP-50 is four times higher. Considering relatively equal chromatographic behavior of alkali metal ions in nitric and hydrochloric solutions [36,37,38], a similar tendency is observed for ions of other alkali metals (Figure 6).
Capacity factor k’ was transformed into the mass distribution ratio Dm via the known relation: D m = k ε ρ a p p , where ε denotes the fraction of sorbent free volume; ρ a p p , denotes apparent density of sorbent. The manufacturer’s data for both Dowex and AG resin types are close and the values ε = 0.38 and ρ a p p = 0.8 g/mL may be used for a first approximation [39].
Considering that the alkali metal ions except Fr(I) were studied in batch experiments [28,38], the data consistency is quite satisfactory and allows us to conclude that the heavier the alkali metal ion, the more difference in its adsorption onto normal and macroreticular cation exchange resins is observed.

3.3. Extraction of 213Bi

The advantage of a two-column generator is the ability to perform desorption of the product with any of the most convenient complexing agents. In the case of a single-column generator, the eluent should be selected in such a manner as to efficiently transfer the daughter radionuclide into the solution and minimize the breakthrough of the parent radionuclide as well. If the parent and daughter radionuclides are kept in equilibrium and are simultaneously separated in space, for example, they are held by different columns, then there is no such limitation. Desorption of 213Bi can be carried out directly by a chelator or even by a chelator–protein conjugate, in which case the labeling takes place in the column and a ready-to-use radiopharmaceutical is obtained in the eluate. After desorption of 213Bi, the second column is washed with the solution used at the stage of its accumulation or it is replaced with a new one and the generator is ready for the next cycle.
A 0.1M HCl/0.1M KI solution is used for 213Bi desorption in a single-column generator. This solution is convenient because Bi(III) forms strong complexes with halide ions, in particular, stable complexes BiI 4 / BiI 5 2 are formed with iodides [40], while Ac(III) does not form such strong complexes. The low acid content in the resulting eluate allows the quick creation of the medium suitable for labeling (pH 5–7) by adding a small volume of buffer. The desorption of 213Bi from a second column containing AG MP-50 resin with a 0.1M HCl/0.1M KI solution was studied. The overall efficiency of the "Afrabis" generator system was evaluated, provided that the accumulation stage was carried out by circulating 0.25 M HNO3 solution for ~4 h and 213Bi was stripped off with 0.1M HCl/0.1M KI solution. The efficiency of the generator “Afrabis” that depends on the flow rate of the eluent during circulation is shown in Figure 7. The efficiency values for the first portion of eluate (0.5 mL) and for the whole fraction (3 mL) are given. The desorption rate of the eluent was constant at 1 mL/min. It can be seen that the 213Bi yield increases with an increase of the flow rate during the accumulation stage and after 1 mL/min it reaches a plateau approaching 75% in the first 0.5 mL of the eluate and 90% in 3 mL.
A series of elutions with a constant flow rate at the accumulation stage and subsequent desorption of the product (1 mL/min) was performed to study the stability of the system. The average yield of 213Bi was 73 ± 2% in the first 0.5 mL of the eluate.
The elution of 213Bi can also be carried out with 1 M HCl solution. The advantage of this approach is the high stability of a 1 M HCl solution unlike 0.1M HCl/0.1M KI and a small volume of eluent (0.5–1.0 mL) can be quickly evaporated using a special heater. The mass distribution ratios Dm, mL/g, of Bi(III) upon sorption onto AG MP-50 as a function of HCl concentrations are given in Figure 8. It can be seen that Dm of Bi(III) becomes negligible for a HCl concentration higher than 0.5 M. At the same time, the retention of parent Ac in 1 M HCl is lower than in 0.1M HCl/0.1M KI, which can affect the service life of a single-column generator. In the case of a two-column generator, there is no such a problem and the efficiency for desorption with 1 M HCl is as high as for a 0.1M HCl/0.1M KI solution.
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and diethylenetriaminepentaacetic acid (DTPA) are the most often used in clinical medicine, although much of the new chelating ligands for Bi(III) are being synthesized and presently actively studied [41]. That is why these compounds were taken as test chelators for Bi desorption from the second column of the generator “Afrabis”.
The DTPA ligand forms a stable complex with Bi(III) (lgK (Bi-DTPA) = 35.2 [42]), which is formed in a few minutes and is already at room temperature. Due to its fast kinetics, DTPA is well suited for dynamic chelation, i.e., for desorption of 213Bi from the second column of the generator “Afrabis” in contrast to static chelation performed in batch conditions. The elution efficiencies of Bi from the column filled with AG MP-50 depending on the DTPA concentration and pH of the eluent are presented in Figure 9. Even at a concentration of 10−5 M, the desorption efficiency is close to 90% (213Bi distribution in other parts of the chromatographic system is not taken into account) and increases with an increase in the concentration of the ligand. The desorption efficiency also slightly increases with an increase of the pH value of solution. This effect is probably related to the kinetics of complex formation. At a constant DTPA concentration, the rate of complex formation decreases as pH rises. A similar dependence is observed for the kinetics of the formation of DTPA complexes with lanthanides [43].
Integral (% of activity in the eluate) and differential (%/0.1 mL) 213Bi elution curves are shown in Figure 10. The typical elution was conducted with 10−5 M DTPA with a pH 5.3. About 85% of 213Bi is eluted with the first 1.0 mL of the solution. For comparison, the same figure shows the elution curves of 213Bi with 0.1 M HCl/0.1 M HI for the conventional single-column generator based on AG MP-50 (discussed in 3.5). It can be observed that, in comparison with iodide complexes, the kinetics of Bi-DTPA complex formation is slower, but the overall desorption efficiency with DTPA solution is higher than with 0.1M HCl/0.1M KI.
Another widely used ligand is DOTA, an azacrown compound that is often referred to as the "gold standard" for many cations. It forms stable complexes (lgK (Bi-DOTA) = 30.3 [44]), while its main disadvantage is a slow rate of binding with most radionuclides. Thus, according to the literature data, the complexation with Bi must be carried out at heating and at 60–100 °C it will take 5–15 min [45]. For this reason, it is unsuitable to carry out the desorption of Bi(III) with a DOTA solution in a dynamic condition. However, the AG MP-50 sorbent can be quickly removed from the column and DOTA is labeled in a static regime by mixing the sorbent with the ligand solution at heating. It is found that the desorption with 3 mL 10−5 M DOTA solution (pH 5.3) under static conditions at a temperature of 90 ± 3 °С results in the binding of 80 ± 3% 207Bi in 5 min. In this case, there is no need to separate the non-complexed part of the radionuclide, since it remains bound on the cation-exchange sorbent.

3.4. Radionuclide Purity of 213Bi Extracted from the Generator “Afrabis”

It is a matter for the near future when the part of 225Ac applied as a source for 213Bi generation is produced with the admixture of long-lived 227Ac. More stringent requirements will be imposed on the radionuclide purity of the 213Bi eluate in this case. In the generator “Afrabis”, due to the non-aggressive mobile phase (weakly acidic or neutral saline solution) used for the 213Bi accumulation stage, 225,227Ac radioisotopes are strongly bound onto the Actinide Resin column. Less than 0.2% of actinium was reported to be washed out of the mother column after one month of daily four hour generation cycles [46]. The actinium breakthrough was then effectively fixed on the second column preventing the final 213Bi from the impurity of actinium radioisotopes.
The influence of relatively long-lived decay products of 227Ac, namely 227Th and 223Ra, on the radionuclidic purity of 213Bi eluate is also important. Starting from the initial 227Ac/225Ac ratio ~0.2% at EOB and assuming null presence of 227Th and 223Ra at the moment of generator loading, the content of 227Ac, 227Th, and 223Ra grows up to 4.2%, 2.8%, and 1.7%, respectively, by the end-of-month generator operation. 227Th is retained by the sorbents of both columns no less firmly than actinium [33]. In contrast, the adsorption of 223Ra depends, to a greater extent, on solution acidity. For the example of 0.25 M HNO3 solution circulating in the system at the stage of 213Bi accumulation, the k’ value of Ra(II) on Actinide Resin falls within 20–30 [33], i.e., 223Ra is quite easily eluted from the mother column.
Scans of total activity produced by 225,227Ac and 227Th permanently adsorbed on the Actinide Resin column as a function of number of elutions or of a total volume of 0.25 M HNO3 solution passed through the column are shown in Figure 11. It can be observed that the initial location of 225,227Ac and 227Th in the first third of the column is slightly displaced after passing 6 L of the solution.
Since 223Ra is being removed in every generation cycle from the Actinide Resin column, the chromatographic system does not work as a double trap, which is the case of actinium and thorium radioisotopes. 223Ra is concentrated together with 213Bi on the second AG MP-50 column. According to the results presented in Figure 8, the Dm value of Ra(II) in 0.25 M HNO3 solution reaches 105 mL/g, while the Dm Ra(II) in 0.1 M HCl/0.1 M HI solution used for 213Bi elution decreases down to 1.2∙104 mL/g. Although the adsorption of radium on AG MP-50 is rather strong, some 223Ra breakthrough into the 213Bi eluate is possible, especially when 213Bi is eluted with certain ligand solutions such as DTPA.
There were two opportunities considered for the periodic elimination of 223Ra from the generator. The first method was to replace the second AG MP-50 column with a new one after each generation cycle and, hence, 223Ra produced from 227Th between the cycles will be transferred to the second column. Otherwise, the mother column can be preconditioned before a generation cycle as it is shown in Figure 1, i.e., it can be preliminary washed with 0.25 M HNO3 or saline solution for removing 223Ra from the system. In this case, 223Ra produced from 227Th during only a single cycle is concentrated on the second column and accumulated from one cycle to another. Finally, we can combine the two opportunities. Figure 12 illustrates estimations of maximal 223Ra amount residing in the generator “Afrabis” in the course of a months work proceeding from the premises that 213Bi is generated once a day and one cycle’s duration is four hours.
Obviously, the least content of 223Ra is achieved by both preconditioning the mother column and replacing the second column. However, the generator maintenance becomes rather tedious so far and that is why the scheme including only the preconditioning was chosen for experimental trial. As a result of a months generator operation following the procedure given in Section 2.5, it was found that the impurities of 225Ac, 227Th, and 223Ra in 0.5 mL of the 213Bi eluate did not exceed 10−6% (detection limit), while the impurity of 227Ac estimated from the initial 227Ac/225Ac ratio was less than 10−8%.

3.5. Single-Column 225Ac/213Bi Generator with AG MP-50

Single-column "direct" 225Ac/213Bi generator with AG MP-50 resin [12] is the most common for 213Bi production. Clinical tests are carried out using such generators. The parent 225Ac is firmly retained by the sorbent and 213Bi is eluted with a complexing agent. The milking protocol was proposed at the Joint Research Centre in Karlsruhe (JRC, Germany). According to the protocol, 213Bi is eluted with 0.6 mL of 0.1 M NaI/0.1 M HCl solution from a column containing 0.33 mL of AG MP-50. The elution efficiency is reported to be 76 ± 3%, 225Ac breakthrough is less than 2·10−5%. The possible disadvantage of this generator is low radiation resistance of the organic sorbent [25]. Moreover, there are no data on the application of this generator with an accelerator-produced 225Ac containing an impurity of 227Ac and 227Ac decay products—227Th and 223Ra.
A generator based on AG MP-50 was prepared in order to compare its performance with the generator system “Afrabis”. The generator was loaded, stored, and milked according to the procedure described [12] with the only difference being that 225Ac that is obtained by irradiation of thorium with protons (~0.2% 227Ac at the EOB) is applied. As a result of loading of 225Ac in a small volume of 4 M HNO3, the activity deposits on the top two-third part of the column. This approach was proposed by JRC to reduce the influence of radiation impact on the sorbent. Initial distribution of 225Ac in the AG MP-50 column of 225Ac/213Bi generator is shown in Figure A1. It can be seen that the distribution of activity is consistent with the literature data [12].
The results of the generator investigation carried out during 1 month are given in Table 2 in comparison with literature data and the generator “Afrabis” performance.
The typical integral and differential 213Bi elution curves with 0.1M HCl/0.1M KI from the single-column generator with AG MP-50 are shown in Figure 10. The elution efficiency of 213Bi for the single-column generator (67 ± 2% in 0.5 mL) is slightly lower than for the generator “Afrabis” (73 ± 2% in 0.5 mL). At the same time, the estimate of the breakthrough of the parent 225Ac (<3.5 × 10−5%) is consistent with the literature data, which was obtained for higher loaded 225Ac activity. The resulting 225Ac content limit for the generator system “Afrabis” is noticeably lower (<10−6%).
The difference in the degree of purification from 223Ra, which is a decay product of 227Ac, is significant; for a single-column generator, 223Ra activity concentration in the first portion of 213Bi eluate is 10−4–10−3%, while for the generator “Afrabis” the corresponding value is <10−6%. The obtained results are in accordance with theoretical views. Ac(III), Th(IV), and Ra(II) do not form strong iodide and chloride complexes, unlike Bi(III) [40]. Therefore, the retention of these ions by a strongly acidic cation exchange sorbent from the 0.1 M NaI/0.1 M HCl solution increases with their charges in the order Ra(II) < Ac(III) < Th(IV) [39].
It can be concluded that the developed generator “Afrabis” provides 213Bi with a higher radionuclide purity than compared to the conventional generator. The content of the parent radionuclide in 213Bi solution is at least one order of a magnitude lower and 223Ra is at least two orders of a magnitude lower. At the same time, the efficiencies of 213Bi extraction from both generators are similar.

4. Conclusions

A new two-column 225Ac/213Bi generator intended for using the parent 225Ac with 227Ac impurity is proposed and investigated. The formation and concentration of 213Bi on the second column is realized by continuous separation of intermediate 221Fr from 225Ac fixed on the first column. The generator is compact due to circulation of the mobile phase in a closed-loop circuit. In comparison with the generators described in literature, this provides a high product yield with a low breakthrough of actinium isotopes and 227Ac decay products. The concentration of 213Bi on a separate column allows us to desorb it with any convenient complexing agent, including chelation and labeling directly on the column.

Author Contributions

Conceptualization: S.E.; methodology: S.E. and A.S.; validation: S.E., A.S. and A.V.; formal analysis: S.E. and A.S.; investigation: S.E., A.S. and A.V.; writing—original draft preparation: S.E. and A.V.; writing—review and editing: S.E. and A.V.; visualization: S.E. and A.V.; supervision: S.E.; funding acquisition: A.V. All authors have read and agreed to the published version of the manuscript.

Funding

This work has been supported by the Russian Science Foundation under Contracts No. 19-73-00348.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The equipment of the Center for Shared Use of the Institute for Nuclear Research, Russian Academy of Sciences, was used.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Figure A1. Initial distribution of 225Ac in the AG MP-50 column of 225Ac/213Bi generator.
Figure A1. Initial distribution of 225Ac in the AG MP-50 column of 225Ac/213Bi generator.
Pharmaceutics 13 00914 g0a1

References

  1. Ahenkorah, S.; Cassells, I.; Deroose, C.M.; Cardinaels, T.; Burgoyne, A.R.; Bormans, G.; Ooms, M.; Cleeren, F. Bismuth-213 for targeted radionuclide therapy: From atom to bedside. Pharmaceutics 2021, 13, 599. [Google Scholar] [CrossRef] [PubMed]
  2. Morgenstern, A.; Apostolidis, C.; Bruchertseifer, F. Supply and clinical application of actinium-225 and bismuth-213. Semin. Nucl. Med. 2020, 50, 119–123. [Google Scholar] [CrossRef]
  3. Rosenblat, T.L.; McDevitt, M.R.; Mulford, D.A.; Pandit-Taskar, N.; Divgi, C.R.; Panageas, K.S.; Heaney, M.L.; Chanel, S.; Morgenstern, A.; Sgouros, G.; et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res. 2010, 16, 5303–5311. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Schmidt, D.; Neumann, F.; Antke, C.; Apostolidis, C.; Martin, S.; Morgenstern, A.; Molinet, R.; Heeger, S.; Kronenwett, R.; Müller, H.W. Phase I clinical study on alphatherapy for non hodgkin lymphoma. In Proceedings of the 4th Alpha-Immunotherapy Symposium, ITU, Dusseldorf, Germany, 28–29 June 2004; Morgenstern, A., Ed.; ITU: Dusseldorf, Germany, 2004. [Google Scholar]
  5. Autenrieth, M.E.; Seidl, C.; Bruchertseifer, F.; Horn, T.; Kurtz, F.; Feuerecker, B.; D’Alessandria, C.; Pfob, C.; Nekolla, S.; Apostolidis, C.; et al. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: A pilot study. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1364–1371. [Google Scholar] [CrossRef]
  6. Kratochwil, C.; Giesel, F.L.; Bruchertseifer, F.; Mier, W.; Apostolidis, C.; Boll, R.; Murphy, K.; Haberkorn, U.; Morgenstern, A. 213Bi-DOTATOC receptor- targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 2106–2119. [Google Scholar] [CrossRef] [Green Version]
  7. Krolicki, L.; Bruchertseifer, F.; Kunikowska, J.; Koziara, H.; Królicki, B.; Jakuciński, M.; Pawlak, D.; Apostolidis, C.; Mirzadeh, S.; Rola, R.; et al. Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 614–622. [Google Scholar] [CrossRef] [PubMed]
  8. Allen, B.J.; Singla, A.A.; Rizvi, S.M.A.; Graham, P.; Bruchertseifer, F.; Apostolidis, C.; Morgenstern, A. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy 2011, 3, 1041–1050. [Google Scholar] [CrossRef]
  9. Sathekge, M.; Knoesen, O.; Meckel, M.; Modiselle, M.; Vorster, M.; Marx, S. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur. J. Nucl. Med. 2017, 44, 1099–1100. [Google Scholar] [CrossRef] [Green Version]
  10. Kratochwil, C.; Bruchertseifer, F.; Rathke, H.; Bronzel, M.; Apostolidis, C.; Weichert, W.; Haberkorn, U.; Giesel, F.L.; Morgenstern, A. Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Dosimetry estimate and empiric dose finding. J. Nucl. Med. 2017, 58, 1624–1631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Zacherl, M.J.; Gildehaus, F.J.; Mittlmeier, L.; Boening, G.; Gosewisch, A.; Wenter, V.; Unterrainer, M.; Schmidt-Hegemann, N.; Belka, C.; Kretschmer, A.; et al. First clinical results for PSMA targeted alpha therapy using 225 Ac-PSMA-I&T in advanced mCRPC patients. J. Nucl. Med. 2021, 62, 669–674. [Google Scholar] [CrossRef]
  12. Morgenstern, A.; Bruchertseifer, F.; Apostolidis, C. Bismuth-213 and actinium-225–generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes. Curr. Radiopharm. 2012, 5, 221–227. [Google Scholar] [CrossRef] [PubMed]
  13. McAlister, D.R.; Horwitz, E.P. Automated two column generator systems for medical radionuclides. Appl. Radiat. Isot. 2009, 67, 1985–1991. [Google Scholar] [CrossRef]
  14. Sinenko, I.L.; Kalmykova, T.P.; Likhosherstova, D.V.; Egorova, B.V.; Zubenko, A.D.; Vasiliev, A.N.; Ermolaev, S.V.; Lapshina, E.V.; Ostapenko, V.S.; Fedorova, O.A.; et al. 213Bi production and complexation with new picolinate containing ligands. J. Radioanal. Nucl. Chem. 2019, 321, 531–540. [Google Scholar] [CrossRef]
  15. Bray, L.A.; Tingey, J.M.; DesChane, J.R.; Egorov, O.B.; Tenforde, T.S.; Wilbur, D.S.; Hamlin, D.K.; Pathare, P.M. Development of a Unique Bismuth (Bi-213) automated generator for use in cancer therapy. Ind. Eng. Chem. Res. 2000, 39, 3189–3194. [Google Scholar] [CrossRef]
  16. Betenekov, N.D.; Denisov, E.I.; Vasiliev, A.N.; Ermolaev, S.V.; Zhuikov, B.L. Perspectives for Ac-225/Bi-213 generator developing using hydroxide inorganic sorbents. Radiochemistry 2019, 61, 211–219. [Google Scholar] [CrossRef]
  17. Vasiliev, A.N.; Ermolaev, S.V.; Lapshina, E.V.; Zhuikov, B.L.; Betenekov, N.D. 225Ac/213Bi generator based on inorganic sorbents. Radiochim. Acta 2019, 107, 1203–1211. [Google Scholar] [CrossRef]
  18. Zhuikov, B.L.; Kalmykov, S.N.; Ermolaev, S.V.; Aliev, R.A.; Kokhanyuk, V.M.; Matushko, V.L.; Tananaev, I.G.; Myasoedov, B.F. Production of 225Ac and 223Ra by irradiation of Th with accelerated protons. Radiochemistry 2011, 53, 73–80. [Google Scholar] [CrossRef]
  19. Ermolaev, S.V.; Zhuikov, B.L.; Kokhanyuk, V.M.; Matushko, V.L.; Kalmykov, S.N.; Aliev, R.A.; Tananaev, I.G.; Myasoedov, B.F. Production of actinium, thorium and radium isotopes from natural thorium irradiated with protons up to 141 MeV. Radiochim. Acta 2012, 100, 223–229. [Google Scholar] [CrossRef]
  20. Aliev, R.A.; Ermolaev, S.V.; Vasiliev, A.N.; Ostapenko, V.S.; Lapshina, E.V.; Zhuikov, B.L.; Zakharov, N.V.; Pozdeev, V.V.; Kokhanyuk, V.M.; Myasoedov, B.F.; et al. Isolation of medicine-applicable actinium-225 from thorium targets irradiated by medium-energy protons. Solvent Extr. Ion Exch. 2014, 32, 468. [Google Scholar] [CrossRef]
  21. Zhuikov, B.L.; Ermolaev, S.V. Radioisotope research and development at the linear accelerator of the Institute for Nuclear Research of RAS. Phys. Uspekhi 2021. to be published. [Google Scholar]
  22. Hoehr, C.; Bénard, F.; Buckley, K.; Crawford, J.; Gottberg, A.; Hanemaayer, V.; Kunz, P.; Ladouceur, K.; Radchenko, V.; Ramogida, C.; et al. Medical isotope production at TRIUMF-from imaging to treatment. Phys. Procedia 2017, 90, 200–208. [Google Scholar] [CrossRef]
  23. John, K. US DOE tri-lab research and production effort to provide accelerator- produced 225Ac for radiotherapy: 2019 update. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, S722. [Google Scholar] [CrossRef]
  24. Sgouros, G.; Frey, E.; He, B.; Ray, N.; Ludwig, D. Dosimetric Impact of Ac-227 in Accelerator-Produced Ac-225. J. Med. Imaging Radiat. Sci. 2019, 50, S37–S38. [Google Scholar] [CrossRef]
  25. Vasiliev, A.N.; Zobnin, V.A.; Pavlov, Y.S.; Chudakov, V.M. Radiation stability of sorbents in medical 225Ac/213Bi generators. Solvent Extr. Ion Exch. 2021, 39, 353–372. [Google Scholar] [CrossRef]
  26. Brookhaven National Laboratory. National Nuclear Data Center. Available online: http://www.nndc.bnl.gov/nudat2/ (accessed on 30 April 2021).
  27. Vasiliev, A.N.; Ostapenko, V.S.; Lapshina, E.V.; Ermolaev, S.V.; Danilov, S.S.; Zhuikov, B.L.; Kalmykov, S.N. Recovery of Ra-223 from natural thorium irradiated by protons. Radiochim. Acta 2016, 104, 539–547. [Google Scholar] [CrossRef]
  28. Strelow, F.W. Distribution coefficients and ion exchange behavior of 46 elements with a macroreticular cation exchange resin in hydrochloric acid. Anal. Chem. 1984, 56, 1053–1056. [Google Scholar] [CrossRef]
  29. Ostapenko, V.; Vasiliev, A.; Lapshina, E.; Ermolaev, S.; Aliev, R.; Totskiy, Y.; Zhuikov, B.; Kalmykov, S. Extraction chromatographic behavior of actinium and REE on DGA, Ln and TRU resins in nitric acid solutions. J. Radioanal. Nucl. Chem. 2015, 306, 707–711. [Google Scholar] [CrossRef]
  30. Ermolaev, S.V.; Skasyrskaya, A.K. Motion of genetically related 221Fr and 213Bi radionuclides in a chromatographic medium. Radiochemistry 2019, 61, 44–54. [Google Scholar] [CrossRef]
  31. Apostolidis, C.; Molinet, R.; Rasmussen, G.; Morgenstern, A. Production of Ac-225 from Th-229 for targeted α therapy. Anal. Chem. 2005, 77, 6288–6291. [Google Scholar] [CrossRef]
  32. Rösch, F.; Knapp, F.F. Radionuclide generators. In Radiochemistry and Radiopharmaceutical Chemistry in Life Sciences, 1st ed.; Vértes, A., Nagy, S., Klencsár, Z., Rösch, F., Eds.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 2003; pp. 81–118. [Google Scholar]
  33. Horwitz, E.P.; Chiarizia, R.; Dietz, M.L. DIPEX: A new extraction chromatographic material for the separation and preconcentration of actinides from aqueous solution. React. Funct. Polym. 1997, 33, 25–36. [Google Scholar] [CrossRef]
  34. Wu, C.; Brechbiel, M.W.; Gansow, O.A. An improved generator for the production of 213Bi from 225Ac. Radiochim. Acta 1997, 79, 141–144. [Google Scholar] [CrossRef]
  35. Betenekov, N.D.; Ermolaev, S.V.; Skasyrskaya, A.K. Development of a 225Ac/213Bi generator with two inorganic sorbents. Processes involving radionuclides of the 225Ac subfamily. Radiochemistry 2020, 62, 524–531. [Google Scholar] [CrossRef]
  36. Strelow, F.W.E. Comparative distribution coefficients for some elements with a macroporous cation exchange resin in HNO3 and HCl. Solvent Extr. Ion Exch. 1988, 6, 323–334. [Google Scholar] [CrossRef]
  37. Strelow, F.W.E. An ion exchange selectivity scale of cations based on equilibrium distribution coefficients. Anal. Chem. 1960, 32, 1185–1188. [Google Scholar] [CrossRef]
  38. Strelow, F.W.; Rethemeyer, R.; Bothma, C.J.C. Ion exchange selectivity scales for cations in nitric acid and sulfuric acid media with a sulfonated polystyrene resin. Anal. Chem. 1965, 37, 106–111. [Google Scholar] [CrossRef]
  39. Marhol, M. Ion exchangers in analytical chemistry. Their properties and use in inorganic chemistry. In Wilson and Wilson’s Comprehensive Analytical Chemistry; Elsevier Scientific Pub. Co.: Amsterdam, The Netherlands, 1982; Volume 34. [Google Scholar]
  40. Spivakov, B.Y.; Stoyanov, E.S.; Gribov, L.A.; Zolotov, Y.A. Raman laser spectroscopic studies of bismuth (III) halide complexes in aqueous solutions. J. Inorg. Nucl. Chem. 1979, 41, 453–455. [Google Scholar] [CrossRef]
  41. Egorova, B.V.; Fedorova, O.A.; Kalmykov, S.N. Cationic radionuclides and ligands for targeted therapeutic radiopharmaceuticals. Russ. Chem. Rev. 2019, 88, 901. [Google Scholar] [CrossRef]
  42. Montavon, G.; Le Du, A.; Champion, J.; Rabung, T.; Morgenstern, A. DTPA complexation of bismuth in human blood serum. Dalton Trans. 2012, 41, 8615. [Google Scholar] [CrossRef]
  43. Nash, K.L.; Brigham, D.; Shehee, T.C.; Martin, A. The kinetics of lanthanide complexation by EDTA and DTPA in lactate media. Dalton Trans. 2012, 41, 14547–14556. [Google Scholar] [CrossRef]
  44. Csajbók, É.; Baranyai, Z.; Bányai, I.; Brücher, E.; Király, R.; Müller-Fahrnow, A.; Platzek, J.; Radüchel, B.; Schäfer, M. Equilibrium, 1H and 13C NMR spectroscopy, and X-ray diffraction studies on the complexes Bi (DOTA)-and Bi (DO3A-Bu). Inorg. Chem. 2003, 42, 2342–2349. [Google Scholar] [CrossRef] [PubMed]
  45. Wild, D.; Frischknecht, M.; Zhang, H.; Morgenstern, A.; Bruchertseifer, F.; Boisclair, J.; Provencher-Bolliger, A.; Reubi, J.-C.; Maecke, H.R. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN). Cancer Res. 2011, 71, 1009–1018. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Ermolaev, S.V.; Skasyrskaya, A.K. Razrabotka tsirkuliruyushchey skhemy polucheniya 213Bi iz 221Fr, nepreryvno otdelyaemogo ot 225Ac. In Book of Abstracts, Proceedings of the IX Russian Conference “Radiochemistry 2018”; Saint-Petersburg, Russia, 17–21 September 2018, Myasoedov, B.F., Kalmykov, S.N., Petrov, V.G., Eds.; Rosatom: Saint-Petersburg, Russia, 2018. [Google Scholar]
Figure 1. Scheme (a) and photo (b) of a laboratory 225Ас/213Bi generator “Afrabis”. 1—chromatographic column with parent 225Ac; 2—chromatographic column for 213Bi accumulation; 3—peristaltic pump; 4—three-way cock.
Figure 1. Scheme (a) and photo (b) of a laboratory 225Ас/213Bi generator “Afrabis”. 1—chromatographic column with parent 225Ac; 2—chromatographic column for 213Bi accumulation; 3—peristaltic pump; 4—three-way cock.
Pharmaceutics 13 00914 g001
Figure 2. Differential (mL−1) elution curve of 221Fr eluted from the column containing 0.3 mL Actinide Resin with 0.0025 M NH4Cl solution passing at flow rate of 1.0 ± 0.1 mL/min. A dotted histogram and a solid curve represent experimental data and a fitting line, respectively. Designations: A 2 i 221Fr activity in an i portion of plateau elution corrected for decay to the end of portion sampling; A 1 0 225Ac activity at the start of elution; V c q 2 —residence time of 221Fr in the chromatographic column (see explanation in the text below).
Figure 2. Differential (mL−1) elution curve of 221Fr eluted from the column containing 0.3 mL Actinide Resin with 0.0025 M NH4Cl solution passing at flow rate of 1.0 ± 0.1 mL/min. A dotted histogram and a solid curve represent experimental data and a fitting line, respectively. Designations: A 2 i 221Fr activity in an i portion of plateau elution corrected for decay to the end of portion sampling; A 1 0 225Ac activity at the start of elution; V c q 2 —residence time of 221Fr in the chromatographic column (see explanation in the text below).
Pharmaceutics 13 00914 g002
Figure 3. The capacity factor k’ of Fr(I) upon sorption onto Actinide Resin as a function of NaCl and NH4Cl concentrations. The literature data [30] for HNO3 solutions are shown by dotted line.
Figure 3. The capacity factor k’ of Fr(I) upon sorption onto Actinide Resin as a function of NaCl and NH4Cl concentrations. The literature data [30] for HNO3 solutions are shown by dotted line.
Pharmaceutics 13 00914 g003
Figure 4. 213Bi residue on the column containing 0.4 mL Actinide Resin (% to equilibrium activity) depending on the flow rate of mobile phase (0.25 М HNO3) during the accumulation stage.
Figure 4. 213Bi residue on the column containing 0.4 mL Actinide Resin (% to equilibrium activity) depending on the flow rate of mobile phase (0.25 М HNO3) during the accumulation stage.
Pharmaceutics 13 00914 g004
Figure 5. Distribution of 213Bi activity on the series-connected columns with 0.10 mL of AG MP-50, each depending on the flow rate of 0.25 М HNO3 eluent solution.
Figure 5. Distribution of 213Bi activity on the series-connected columns with 0.10 mL of AG MP-50, each depending on the flow rate of 0.25 М HNO3 eluent solution.
Pharmaceutics 13 00914 g005
Figure 6. The mass distribution ratios Dm, mg/mL, of alkali metal ions upon sorption onto Dowex 50 × 8 and AG MP-50 from 0.25 M nitric or hydrochloric acid. Literature data [28,38] are shown by empty circles and squares.
Figure 6. The mass distribution ratios Dm, mg/mL, of alkali metal ions upon sorption onto Dowex 50 × 8 and AG MP-50 from 0.25 M nitric or hydrochloric acid. Literature data [28,38] are shown by empty circles and squares.
Pharmaceutics 13 00914 g006
Figure 7. The elution efficiency of the generator “Afrabis” depending on the flow rate of the eluent (0.25 М HNO3) during circulation. The values for the first portion of eluate (0.5 mL) and for the whole fraction (3 mL) are given.
Figure 7. The elution efficiency of the generator “Afrabis” depending on the flow rate of the eluent (0.25 М HNO3) during circulation. The values for the first portion of eluate (0.5 mL) and for the whole fraction (3 mL) are given.
Pharmaceutics 13 00914 g007
Figure 8. The mass distribution ratios Dm, mg/mL, of Ra(II) and Bi(III) upon sorption onto AG MP-50 as a function of HCl or HNO3 concentrations.
Figure 8. The mass distribution ratios Dm, mg/mL, of Ra(II) and Bi(III) upon sorption onto AG MP-50 as a function of HCl or HNO3 concentrations.
Pharmaceutics 13 00914 g008
Figure 9. The elution efficiencies of Bi from the column with 0.4 mL AG MP-50 depending on the DTPA concentration and pH of the eluent. The volume of DTPA solution is 5 mL; flow rate—1.0 ± 0.1 mL/min.
Figure 9. The elution efficiencies of Bi from the column with 0.4 mL AG MP-50 depending on the DTPA concentration and pH of the eluent. The volume of DTPA solution is 5 mL; flow rate—1.0 ± 0.1 mL/min.
Pharmaceutics 13 00914 g009
Figure 10. Integral (% of activity in the eluate, dashed lines) and differential (%/mL, solid lines) Bi elution curves with 0.1M HCl/0.1M KI and 0.01M DTPA (pH 5.3) from the column with 0.33–0.4 mL AG MP-50. Flow rate—1.0 ± 0.1 mL/min. 213Bi activity was corrected for decay.
Figure 10. Integral (% of activity in the eluate, dashed lines) and differential (%/mL, solid lines) Bi elution curves with 0.1M HCl/0.1M KI and 0.01M DTPA (pH 5.3) from the column with 0.33–0.4 mL AG MP-50. Flow rate—1.0 ± 0.1 mL/min. 213Bi activity was corrected for decay.
Pharmaceutics 13 00914 g010
Figure 11. Distribution of activity along with the length of Actinide Resin column (0.4 mL) in the generator “Afrabis” depending on the number of elutions or the total volume of 0.25 M nitric passed through the column.
Figure 11. Distribution of activity along with the length of Actinide Resin column (0.4 mL) in the generator “Afrabis” depending on the number of elutions or the total volume of 0.25 M nitric passed through the column.
Pharmaceutics 13 00914 g011
Figure 12. Estimation of maximal 223Ra amount in the generator “Afrabis” producing 213Bi once a day in a four hour cycle: 1—without preconditioning the mother column or replacing the second column (black line); 2—with replacing the second column after each cycle (red line); 3—with preconditioning the mother column before each cycle (blue line); 4—with preconditioning the mother column and replacing the second column every time (green line).
Figure 12. Estimation of maximal 223Ra amount in the generator “Afrabis” producing 213Bi once a day in a four hour cycle: 1—without preconditioning the mother column or replacing the second column (black line); 2—with replacing the second column after each cycle (red line); 3—with preconditioning the mother column before each cycle (blue line); 4—with preconditioning the mother column and replacing the second column every time (green line).
Pharmaceutics 13 00914 g012
Table 1. Capacity factors k’ of Fr(I) and Bi(III) adsorbed onto various sorbents.
Table 1. Capacity factors k’ of Fr(I) and Bi(III) adsorbed onto various sorbents.
Stationary Phase (Sorbent)Mobile Phase
(Solution)
k’ Fr(I)k’ Bi(III)
AMP-PAN (Triskem) 10.25 M HNO32.5·102>3·104
Dowex 50 × 8 (Dow) 10.25 M HNO3102>6·104
T-35 (Termoxid) 21 M NH4Cl, pH 6.85·102>5·104
AG MP-50 (BioRad)0.25 M HNO34·102>5·104
AG MP-50 (BioRad)0.017 M NaCl, pH ~6103>5·104
Literature data: 1 [30], 2 [35].
Table 2. Results of 213Bi elution from the single-column 225Ac/213Bi generator with AG MP-50 resin.
Table 2. Results of 213Bi elution from the single-column 225Ac/213Bi generator with AG MP-50 resin.
225Ac/213Bi GeneratorEfficiency of 213Bi Elution, %/in the First 0.5 mL of EluateImpurity in the First Eluate Portion of 0.5 mL, %
225Ac227Ac227Th223Ra
“Afrabis”73 ± 2<10−6<10−8 **<10−6<10−6
JRC (Karlsruhe, Germany)67 ± 2
76 ± 3 [10] *
<3.5·10−5
2·10−5 [10] *
<10−6 **<10−610−4–10−3
* For first 0.6 mL of eluate; ** (estimated by 225Ac).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Ermolaev, S.; Skasyrskaya, A.; Vasiliev, A. A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling. Pharmaceutics 2021, 13, 914. https://doi.org/10.3390/pharmaceutics13060914

AMA Style

Ermolaev S, Skasyrskaya A, Vasiliev A. A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling. Pharmaceutics. 2021; 13(6):914. https://doi.org/10.3390/pharmaceutics13060914

Chicago/Turabian Style

Ermolaev, Stanislav, Aino Skasyrskaya, and Aleksandr Vasiliev. 2021. "A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling" Pharmaceutics 13, no. 6: 914. https://doi.org/10.3390/pharmaceutics13060914

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop